Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Long-Term Investments: 2016-2017

Historic Long-Term Investments for Organogenesis Holdings (ORGO) over the last 2 years, with Dec 2017 value amounting to $312.5 million.

  • Organogenesis Holdings' Long-Term Investments rose 1.48% to $316.3 million in Q3 2018 from the same period last year, while for Sep 2018 it was $316.3 million, marking a year-over-year increase of 1.48%. This contributed to the annual value of $312.5 million for FY2017, which is 0.81% up from last year.
  • As of FY2017, Organogenesis Holdings' Long-Term Investments stood at $312.5 million, which was up 0.81% from $310.0 million recorded in FY2016.
  • Over the past 5 years, Organogenesis Holdings' Long-Term Investments peaked at $312.5 million during FY2017, and registered a low of $310.0 million during FY2016.
  • Its 2-year average for Long-Term Investments is $311.2 million, with a median of $311.2 million in 2016.
  • Data for Organogenesis Holdings' Long-Term Investments shows a peak YoY grew of 0.81% (in 2017) over the last 5 years.
  • Organogenesis Holdings' Long-Term Investments (Yearly) stood at $310.0 million in 2016, then climbed by 0.81% to $312.5 million in 2017.